Selexipag, also known as ACT-293987 and NS-304, is a a first-in-class orally available selective non-prostanoid IP receptor agonist, which is currently in development by Actelion as a treatment of pulmonary arterial hypertension. Selexipag and its active metabolite, ACT-333679, are agonists at the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.
Prostaglandin Receptor Related Products:
E-7046; Ramatroban; Ozagrel; Bimatoprost; Prostaglandin E2; Tafluprost; Carboprost; Treprostinil sodium; MRE-269; Travoprost; Misoprostol; Setipiprant